A randomised controlled trial of outpatient Morita therapy for clients with anxiety
Phase 2
Recruiting
- Conditions
- Anxiety disorders, obsessive-compulsive and related disorders in the DSM-5, or patient/client-reported anxiety equivalent to them.
- Registration Number
- JPRN-UMIN000041277
- Lead Sponsor
- Japanese Society for Morita Therapy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
Active Individuals who: - are self-injurious/harming - are actively suicidal - are diagnosed with developmental disabilities
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome measure: The Generalized Anxiety Disorder (GAD-7)
- Secondary Outcome Measures
Name Time Method Secondary outcome measures: The Patient Health Questionnaire (PHQ)-9 the Japanese General Health Questionnaire (GHQ-12) Self-Kindness Subscale of the Self-Compassion Scale the Japanese version of the Sheehan Disability Scale The Morita Attitudinal Scale for Arugamama (MASA) The outcome measures will be routinely administered to both treatment and control groups, at the pre- (1st session), mid- (6th session), and post treatment (12th session) time points. Follow-up administrations of the measures will be conducted only with the treatment group at 3, 6, 12 months post-treatment time points. Qualitative evaluation: Semi-structured interviews will be conducted with both treatment and control groups at the exact same time points as the administrations of the outcome measures. : Interview questions: (a) What are you anxious about at the present moment?, (b) What was it like for you to take actions? (c) What do you think of yourself now?